- |||||||||| dexamethasone / Generic mfg., hydrocortisone / Generic mfg.
New Atopic-Like 3D Epidermal Model For Active In Vitro Evaluation () - Jul 3, 2023 - Abstract #WCD2023WCD_3863;
Also, an evaluation protocol was optimized on the compromised RHE shLUC model with 2 well known anti-inflammatory pharmaceutical references (dexamethasone, hydrocortisone). These encouraging results demonstrate that this protocol on compromised RHE tissues is a relevant and promising tool for the screening of active ingredients or even formulations for new preventive or therapeutic strategies in the field of moderate AD.
- |||||||||| Xolair (omalizumab) / Roche, Novartis
Refractory Vasoplegia After Cosmetic Use Of Hyaluronic Acid: A Rare Complication Associated With Mast Cell Activation Syndrome (Mcas) () - Jul 3, 2023 - Abstract #WCD2023WCD_3829;
She had already presented hemodynamic instability 13 years ago due to a hormonal implant that resolved after its removal and was under omalizumab therapy for 2 years...Ten days after she was admitted to the intensive care unit and was treated with intravenous fluids and hydrocortisone with no response...There is no report in the literature of HA filler as a trigger for mast cell activation. Every injector must be aware of this possibility and be prepared to handle this complication
- |||||||||| hydrocortisone / Generic mfg.
Preclinical, Journal: Wound Restorative Power of Halimeda macroloba/ Mesenchymal Stem Cells in Immunocompromised Rats via Downregulating Inflammatory/Immune Cross Talk. (Pubmed Central) - Jul 1, 2023
Twelve days after inducing immunocompromise (40 mg/kg hydrocortisone daily), a circular excision was created in the dorsal skin of rats and the treatments were continued for 16 days...RT-PCR gene expression analysis revealed that the BMMSCs/Halimeda extract combination had perfectly attenuated oxidative stress, proinflammatory cytokines, and NF-B activation at day 16 of wounding. The combination holds promise for regenerative medicine, representing a revolutionary step in the wound healing of immunocompromised patients, with still a need for safety assessments and further clinical trials.
- |||||||||| cabergoline / Generic mfg., hydrocortisone / Generic mfg.
Journal: Diagnosis and management of pituitary apoplexy: a Tunisian data. (Pubmed Central) - Jul 1, 2023
To conclude, pituitary apoplexy is a challenging condition due to its variable course, its diagnosis difficulty and management, as gaps remain to determine the best approach to treat this condition. Further studies are thus needed.
- |||||||||| hydrocortisone / Generic mfg., epinephrine / Generic mfg.
Journal: Management of mad honey intoxication with suspected anaphylaxis in Nepal: a case report. (Pubmed Central) - Jun 26, 2023
This commentary aims to guide clinicians on the alternative to hydrocortisone among septic shock patients due to medication shortage. He again developed hypotension and bradycardia in a few hours, for which hydrocortisone was administered, following which his heart rate was normalized in 2
- |||||||||| Mifeprex (mifepristone) / Danco Laboratories
Review: Pharmacological memory modulation to augment trauma-focused psychotherapy for PTSD: a systematic review of randomised controlled trials. (Pubmed Central) - Jun 20, 2023
Seven studies showed no significant effect of pharmacological augmentation compared to placebo (D-cycloserine, rapamycin, mifepristone, propranolol, mifepristone combined with D-cycloserine, methylene blue)...Results of pharmacological augmentation were mixed overall and heterogenous for the pharmacological agents tested in more than one study. Additional studies and replications are needed to identify which pharmacological agents work, in which combination and to identify patient groups that benefit most to tailor PTSD treatment.
- |||||||||| hydrocortisone / Generic mfg.
Journal: Development of 3D printed mini-waffle shapes containing hydrocortisone for children's personalized medicine. (Pubmed Central) - Jun 16, 2023
Mass and content uniformity, hardness and friability tests complied with European Pharmacopeia specifications, despite the considerable challenge of the small dimensions of the forms. This study demonstrates that FDM can be used to produce innovative pediatric-friendly printed shapes of an advanced pharmaceutical quality to practice personalize medicine.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, idasanutlin (RG7388) / Roche
Trial completion date, Trial primary completion date, Combination therapy: A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors (clinicaltrials.gov) - Jun 15, 2023
P1/2, N=183, Recruiting,
The study clearly indicated the effects of glucocorticoids on adrenocortical function in horses and provided basic knowledge about the selection and prescription of glucocorticoid preparations and setting the withdrawal times in equine clinical setting. Trial completion date: May 2024 --> Dec 2025 | Trial primary completion date: May 2024 --> Dec 2025
- |||||||||| hydrocortisone / Generic mfg.
Allergy induced by bethamethasone phosphate after intra-articular infiltration (Poster Zone A) - Jun 9, 2023 - Abstract #EAACI2023EAACI_2524;
Trial primary completion date: Jun 2022 --> Dec 2024 Hydrocortisone and methylprednisolone succinate esters are the most frequent substances triggering immediate type adverse reactions, while halogenated corticosteroids are rarely involved...The auscultation and blood oxygen levels (SpO2) were normal.
- |||||||||| hydrocortisone / Generic mfg.
Journal: Effects of combined cannabidiol (CBD) and hops (Humulus lupulus) terpene extract treatment on RAW 264.7 macrophage viability and inflammatory markers. (Pubmed Central) - Jun 7, 2023
The combination of CBD and Hops 1 showed effects in LPS-stimulated RAW 264.7 cells superior to the single substance treatments and akin to the control hydrocortisone...The anti-inflammatory effect of CBD and its cellular uptake positively correlated with terpene concentration, as indicated by comparison with a hemp extract containing both CBD and terpenes. These findings may contribute to the postulations for the so-called "entourage effect" between cannabinoids and terpenes and support the potential of CBD combined with phytomolecules from a non-cannabinoid source, such as hops, for the treatment of inflammatory diseases.
- |||||||||| hydrocortisone / Generic mfg.
Clinical, Journal: What a difference timing makes: Cortisol effects on neural underpinnings of emotion regulation. (Pubmed Central) - Jun 5, 2023
These findings may contribute to the postulations for the so-called "entourage effect" between cannabinoids and terpenes and support the potential of CBD combined with phytomolecules from a non-cannabinoid source, such as hops, for the treatment of inflammatory diseases. In this randomized, double-blind, placebo-controlled neuroimaging experiment, 105 participants (54 men, 51 women) received 20
- |||||||||| Adcetris (brentuximab vedotin) / Takeda, Pfizer, Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date, Immuno-oncology: AHOD2131: A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (clinicaltrials.gov) - Jun 5, 2023
P3, N=1875, Recruiting,
In this randomized, double-blind, placebo-controlled neuroimaging experiment, 105 participants (54 men, 51 women) received 20 Trial completion date: Jun 2030 --> Apr 2031 | Trial primary completion date: Jun 2030 --> Apr 2031
- |||||||||| hydrocortisone / Generic mfg., flutamide / Generic mfg.
Phase classification, Trial completion date, Trial primary completion date, Combination therapy: Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia (clinicaltrials.gov) - Jun 5, 2023
P4, N=62, Active, not recruiting,
Trial completion date: Dec 2025 --> Feb 2028 | Trial primary completion date: Dec 2023 --> Feb 2026 Phase classification: P2 --> P4 | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2022
- |||||||||| hydrocortisone / Generic mfg.
Journal: Protective Effects of Different Doses of Ginsenoside-Rb1 Experimental Cataract Model that in Chick Embryos. (Pubmed Central) - Jun 1, 2023
Five different experimental groups were formed with 100 SPF fertilized eggs: Control (0.9% NaCl to physiological saline), hydrocortisone hemisuccinate sodium (HC), low dose (HC?+?L-GRb1 (1?mg/kg)), medium dose (HC+)...1?mg/kg and 2.5?mg/kg GRb1 applications show therapeutic properties on the HC-induced cataract model. This effect is more pronounced at 2.5?mg/kg.
- |||||||||| Pandel (hydrocortisone probutate) / Novartis, Vampex (carbenoxolone gel) / York Pharma
Journal: Discovery of novel inhibitor of 11 beta-hydroxysteroid dehydrogenase type 1 using in silico structure-based screening approach for the treatment of type 2 diabetes. (Pubmed Central) - May 31, 2023
The binding energies of hydrocortisone succinate, medroxyprogesterone acetate, testolactone, hydrocortisone cypionate, deoxycorticosterone acetate, and hydrocortisone probutate were lower than that of substrate corticosterone...The docking study revealed that hydrocortisone cypionate has a higher binding affinity than carbenoxolone and its other analogs...These findings indicate the potential use of this FDA approved drug in the treatment of type 2 diabetes. However, validation by in vitro inhibitory studies and clinical trials on type 2 diabetes patients is essential to confirm the current findings.
- |||||||||| Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: ACTIVE: A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis (clinicaltrials.gov) - May 31, 2023
P4, N=65, Completed,
However, validation by in vitro inhibitory studies and clinical trials on type 2 diabetes patients is essential to confirm the current findings. Recruiting --> Completed | N=146 --> 65 | Trial completion date: Dec 2023 --> Jan 2023 | Trial primary completion date: Dec 2022 --> Jun 2022
- |||||||||| The B side of intrathecal methotrexate. Case report (Foyer 3B, 3rd Floor) - May 29, 2023 - Abstract #EPNS2023EPNS_900;
Methods A 11-years-old girl with diagnosis of high risk lymphoblastic leukemia type B, receives a cycle of intrathecal therapy based on MTX, hydrocortisone, and cytarabine, as prophylaxis for central nervous system (CNS) involvement...This time theophylline and dextromethorphan were given during the 48 hours before and after the infusion...According to literature, deficits are mostly transient and resolution is complete. Due to the high benefit of MTX intrathecal as prophylaxis of CNS relapse in several hematologic malignancies, and the low rate of neurotoxicity recurrence, this complication should not stop following cycles from being administered.
- |||||||||| hydrocortisone / Generic mfg.
Three cases of cytotoxic lesions of the corpus callosum with different etiologies (Foyer 3B, 3rd Floor) - May 29, 2023 - Abstract #EPNS2023EPNS_732;
However, diffusion restriction in the splenium of the corpus callosum, indicative of transient cytotoxic edema, is typical. CLOCCs should be kept in mind in patients who had acute neurological symptoms with typical MRI findings, even if the symptoms were mild.
- |||||||||| A rare case of CNS hemophagocytic lymphohistiocytosis secondary to dengue fever (Foyer 3B, 3rd Floor) - May 29, 2023 - Abstract #EPNS2023EPNS_530;
On clinical suspicion of HLH work up was done come out to be positive and the patient was started on IV dexamethasone...The patient was started on Intrathecal methotrexate, hydrocortisone and IV etoposide but despite of all the timely initiation of therapy child succumbed on 13th day of illness...Intrathecal methotrexate and corticosteroids have become standard of care in CNS HLH. However, data on value of intrathecal therapy has been limited.
- |||||||||| hydrocortisone / Generic mfg.
Journal: Association of mortality with fludrocortisone addition to hydrocortisone treatment among septic shock patients: a propensity score matching analysis. (Pubmed Central) - May 25, 2023
After PSM, binomial Logistic regression analysis showed that SAPS II score was an independent risk factor for 28-day morality (OR?=?1.04, 95%CI 1.02-1.06, p <?0.01) and in-hospital morality (OR?=?1.04, 95%CI 1.01-1.06, p <?0.01), while hydrocortisone plus fludrocortisone was not an independent risk factor for 90-day mortality (OR?=?0.88, 95%CI 0.43-1.79, p =?0.72), 28-day morality (OR?=?1.50, 95%CI 0.77-2.91, p =?0.24), or in-hospital morality (OR?=?1.58, 95%CI 0.81-3.09, p =?0.18). In the treatment of patients with septic shock, hydrocortisone plus fludrocortisone did not reduce 90-day mortality, 28-day mortality, and in-hospital mortality compared with hydrocortisone alone, and had no effect on the length of hospital stay and ICU stay.
- |||||||||| Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date, Combination therapy: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - May 25, 2023
P3, N=6720, Suspended,
In the treatment of patients with septic shock, hydrocortisone plus fludrocortisone did not reduce 90-day mortality, 28-day mortality, and in-hospital mortality compared with hydrocortisone alone, and had no effect on the length of hospital stay and ICU stay. Trial completion date: Dec 2029 --> Mar 2030 | Trial primary completion date: Dec 2029 --> Mar 2030
- |||||||||| Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Trial completion date, Trial primary completion date, Minimal residual disease: Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia (clinicaltrials.gov) - May 19, 2023
P2, N=32, Recruiting,
These results showed that MMIPs had good performance in selectively identifying hydrocortisone and were suitable for determining hydrocortisone in milk products. Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
|
